S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
This Skill Could Change The Way You Trade! (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
This Skill Could Change The Way You Trade! (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
This Skill Could Change The Way You Trade! (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
This Skill Could Change The Way You Trade! (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
NASDAQ:BLPH

Bellerophon Therapeutics - BLPH Stock Forecast, Price & News

$1.02
0.00 (0.00%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.01
$1.03
50-Day Range
$0.96
$1.20
52-Week Range
$0.67
$3.72
Volume
2,386 shs
Average Volume
4,740 shs
Market Capitalization
$9.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Bellerophon Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
1,762.7% Upside
$19.00 Price Target
Short Interest
Healthy
0.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.50mentions of Bellerophon Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.03) to ($1.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

BLPH stock logo

About Bellerophon Therapeutics (NASDAQ:BLPH) Stock

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Stock News Headlines

Why Are Bellerophon Shares Jumping Today?
See More Headlines
Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Company Calendar

Last Earnings
11/15/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLPH
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+1,762.7%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-17,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.78 per share

Miscellaneous

Free Float
7,187,000
Market Cap
$9.74 million
Optionable
Not Optionable
Beta
-0.06

Key Executives

  • Mr. Peter Fernandes M. Pharm (Age 67)
    Principal Exec. Officer and Chief Regulatory, Safety & Quality Officer
    Comp: $478.84k
  • Dr. Parag Suresh Shah (Age 45)
    VP of Bus. Operations
    Comp: $377.9k
  • Mr. Nicholas Laccona (Age 33)
    Principal Financial & Accounting Officer and Sec.













BLPH Stock - Frequently Asked Questions

What is Bellerophon Therapeutics' stock price forecast for 2023?

0 brokerages have issued twelve-month price objectives for Bellerophon Therapeutics' stock. Their BLPH share price forecasts range from $19.00 to $19.00. On average, they predict the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 1,762.7% from the stock's current price.
View analysts price targets for BLPH
or view top-rated stocks among Wall Street analysts.

How have BLPH shares performed in 2022?

Bellerophon Therapeutics' stock was trading at $3.10 at the beginning of 2022. Since then, BLPH shares have decreased by 67.1% and is now trading at $1.02.
View the best growth stocks for 2022 here
.

Are investors shorting Bellerophon Therapeutics?

Bellerophon Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 17,600 shares, a decrease of 36.9% from the October 31st total of 27,900 shares. Based on an average trading volume of 14,800 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.2% of the shares of the stock are short sold.
View Bellerophon Therapeutics' Short Interest
.

When is Bellerophon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our BLPH earnings forecast
.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.14.

When did Bellerophon Therapeutics' stock split?

Bellerophon Therapeutics's stock reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.62%), Renaissance Technologies LLC (2.06%) and Telemetry Investments L.L.C. (0.50%). Insiders that own company stock include New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends
.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $1.02.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $9.74 million. The biotechnology company earns $-17,760,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.

This page (NASDAQ:BLPH) was last updated on 12/3/2022 by MarketBeat.com Staff